<DOC>
	<DOCNO>NCT02002871</DOCNO>
	<brief_summary>Monocenter , randomize , intraindividual , open label , exploratory study compare 4 week treatment 453nm blue light treatment patient Eczema . Patients screen 28 day start treatment . During screen visit , purpose procedure study explain potential patient informed consent obtain . In addition , fungal superinfection target area examine use direct preparation mycology culture . At baseline visit , patient Eczema determine inclusion exclusion criterion assess . For eligible patient , two comparable treatment area randomize treatment blue light ( target area ) serve untreated control area . After randomization , patient receive treatment target area 3 application per week investigational site total treatment period 4 week . During 4 week , safety effectiveness assessment perform weekly interval . After end treatment , patient followed-up another 2 week . In case full resolution adverse event occur 2 week follow-up visit , follow-up call perform another 2 week . Treatment responses photo document</brief_summary>
	<brief_title>Blue Light Treating Eczema</brief_title>
	<detailed_description />
	<mesh_term>Eczema</mesh_term>
	<criteria>1 . Signed date informed consent prior studymandated procedure 2 . Good health determine Investigator accord physical examination 3 . Willing able comply study requirement 4 . Skin type IIV accord Fitzpatrick 5 . Eczema , severity define Eczema Area Severity Index ( EASI ) smaller/equal 20 6 . Comparable clinical symptomatology intend treatment Areas 8 . Reliable method contraception woman childbearing potential ( i.e . low failure rate le 1 % per year ; e.g . oral contraceptive , intrauterine device [ IUD ] transdermal contraceptive patch ) 9 . Willing abstain excessive sun / UV exposure ( e.g . sunbathe , solarium ) course study 1 . Inmates psychiatric ward , prison , state institution 2 . Investigator team member involve conduct clinical study 3 . Participation another clinical trial within last 30 day 4 . Pregnant lactate woman 5 . Photodermatosis and/or Photosensitivity 6 . Porphyria and/or hypersensitivity porphyrins 7 . Congenital acquire immunodeficiency 8 . Patients follow condition present study area ; Malignoma skin severe actinic damage skin , atypical naevi sign hyperpigmentation , precancerosis viral ( e.g . herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection atrophic skin 9 . Patients genetic deficiency attach increased sensitivity light increase risk dermatologic cancer ( i.e . Xeroderma pigmentosum , Cockayne Syndrome , Bloom Syndrome ) 10 . Current diagnosis exfoliative toxic dermatitis . 11 . Evidence superinfection intend treatment area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>